Qiagen stock holds steady as 2025 revenue and profit metrics frame the setup

Qiagen stock (Qiagen N.V., ISIN NL0012169213) is framed by its latest reported fundamentals: net sales rose 5% on a constant exchange rate basis to $2.07 billion in 2025, adjusted diluted earnings per share reached $2.00, and the adjusted operating profit margin stood at 31% for the year. Those figures remain the clearest reference point for the shares as investors measure the current setup against the companys most recent annual report.

Revenue up 5% in 2025

The 2025 update showed that Qiagens core business kept expanding, with annual sales of $2.07 billion compared with the prior year, when management had reported lower revenue on a constant exchange rate basis. The company also said adjusted net sales growth reached 5% and that adjusted diluted EPS came in at $2.00 for the full year, a combination that points to both growth and profitability rather than volume alone.

For investors, the margin matters as much as the top line. Qiagen reported an adjusted operating profit margin of 31% in 2025, which provides a concrete profitability anchor for how the market can assess execution into 2026.

EPS at $2.00

The earnings line is equally important because it gives a simple comparison point for valuation and sentiment. With adjusted diluted EPS at $2.00 in 2025 and an adjusted operating margin of 31%, Qiagen entered 2026 with a cleaner operating profile than a purely revenue-driven story.

A first-quarter or second-quarter update would normally add a fresher operating read, but the latest fully evidenced figures available here already show the scale of the business. The annual numbers also give context for any move in the shares once new guidance or a quarterly report arrives.

Qiagen sample products

The companys product mix is centered on sample and assay technologies used in molecular testing and life-science workflows. That commercial base is what makes the 2025 revenue and margin figures relevant: the reported $2.07 billion in sales and 31% adjusted operating margin are not abstract numbers, but the financial expression of those recurring platforms.

Stock level watch

Qiagen stock does not have a fresh dated price in this article, so the focus remains on the latest evidenced operating data instead of an unverified quote. The shares can be read against the 2025 baseline of $2.07 billion in net sales, $2.00 adjusted diluted EPS, and a 31% adjusted operating margin as the market waits for the next dated update.